$7.42
1.07% yesterday
NYSE, May 20, 10:00 pm CET
ISIN
US03168L1052
Symbol
AMRX
Sector
Industry

Amneal Pharmaceuticals, Inc. Class A Stock price

$7.42
+0.29 4.07% 1M
-0.99 11.77% 6M
-0.50 6.31% YTD
+0.69 10.25% 1Y
+3.91 111.40% 3Y
+2.85 62.36% 5Y
-7.59 50.57% 10Y
NYSE, Closing price Tue, May 20 2025
-0.08 1.07%
ISIN
US03168L1052
Symbol
AMRX
Sector
Industry

Key metrics

Market capitalization $2.33b
Enterprise Value $4.91b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 20.26
EV/Sales (TTM) EV/Sales 1.74
P/S ratio (TTM) P/S ratio 0.82
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 13.42%
Revenue (TTM) Revenue $2.83b
EBIT (operating result TTM) EBIT $364.68m
Free Cash Flow (TTM) Free Cash Flow $242.44m
Cash position $65.77m
EPS (TTM) EPS $-0.04
P/E forward 53.00
P/S forward 0.77
EV/Sales forward 1.63
Short interest 3.03%
Show more

Is Amneal Pharmaceuticals, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Amneal Pharmaceuticals, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

Buy
100%

Financial data from Amneal Pharmaceuticals, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,830 2,830
13% 13%
100%
- Direct Costs 1,792 1,792
14% 14%
63%
1,038 1,038
13% 13%
37%
- Selling and Administrative Expenses 241 241
13% 13%
9%
- Research and Development Expense 191 191
16% 16%
7%
606 606
12% 12%
21%
- Depreciation and Amortization 241 241
6% 6%
9%
EBIT (Operating Income) EBIT 365 365
17% 17%
13%
Net Profit -13 -13
92% 92%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Amneal Pharmaceuticals, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amneal Pharmaceuticals, Inc. Class A Stock News

Positive
Reuters
6 days ago
Amneal Pharmaceuticals said on Thursday the U.S. Food and Drug Administration has approved its self-administered migraine drug.
Neutral
GlobeNewsWire
6 days ago
Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Dr...
Neutral
GlobeNewsWire
13 days ago
-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal's extensive domestic pharmaceutical manufacturing footprint BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), an American biopharmaceutical company, and...
More Amneal Pharmaceuticals, Inc. Class A News

Company Profile

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Chintu Patel
Employees 8,300
Founded 2002
Website www.amneal.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today